Stockreport

U.S. FDA Accepts Supplemental New Drug Application for NUBEQA® (darolutamide) for the Treatment of Patients with Metastatic Hormone-Sensitive Prostate Cancer [Yahoo! Finance]

ORION CORP NEW UNSP/ADR  (ORINY) 
PDF therapy (ADT) significantly reduced the risk of progression or death in patients with metastatic hormone-sensitive prostate cancer (mHSPC) when compared to placebo plus [Read more]